Overview

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.